Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model

Antimicrob Agents Chemother. 2003 Jun;47(6):1984-7. doi: 10.1128/AAC.47.6.1984-1987.2003.

Abstract

Potential alternatives, including linezolid, adjunctive rifampin, and moxifloxacin, were evaluated against vancomycin-tolerant (P9802-020) and vancomycin-susceptible clinical isolates of Streptococcus pneumoniae in an in vitro pharmacodynamic model. Vancomycin exhibited maximal killing of 2-log(10) CFU/ml against P9802-020. Linezolid, moxifloxacin, and linezolid plus rifampin exhibited 99.9% killing against both isolates. These alternatives should be considered for further evaluation against vancomycin-tolerant S. pneumoniae.

Publication types

  • Comparative Study

MeSH terms

  • Acetamides / pharmacokinetics
  • Acetamides / pharmacology*
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Multiple, Bacterial
  • Drug Therapy, Combination
  • Drug Tolerance
  • Humans
  • Linezolid
  • Microbial Sensitivity Tests
  • Oxazolidinones / pharmacokinetics
  • Oxazolidinones / pharmacology*
  • Pneumococcal Infections / microbiology
  • Rifampin / pharmacokinetics
  • Rifampin / pharmacology*
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / growth & development
  • Streptococcus pneumoniae / isolation & purification
  • Vancomycin / pharmacokinetics
  • Vancomycin / pharmacology*
  • Vancomycin Resistance

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • Vancomycin
  • Linezolid
  • Rifampin